Provided by Tiger Trade Technology Pte. Ltd.

Milestone Pharmaceuticals Inc.

1.20
-0.0100-0.83%
Post-market: 1.210.0100+0.83%19:52 EDT
Volume:1.59M
Turnover:1.94M
Market Cap:148.80M
PE:-1.78
High:1.26
Open:1.21
Low:1.20
Close:1.21
52wk High:3.06
52wk Low:1.00
Shares:124.00M
Float Shares:106.47M
Volume Ratio:1.40
T/O Rate:1.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6748
EPS(LYR):-0.7517
ROE:-35522.62%
ROA:-42.78%
PB:8.17
PE(LYR):-1.60

Loading ...

Milestone Pharmaceuticals Price Target Maintained with a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 04

Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment to the Co

Reuters
·
Sep 03

Milestone Pharmaceuticals - Everest Medicines Holds Exclusive License for Etripamil Nasal Spray in Greater China

THOMSON REUTERS
·
Sep 03

Milestone Pharmaceuticals - Nmpa Approval Triggers $2 Mln Milestone Payment to Milestone Pharmaceuticals

THOMSON REUTERS
·
Sep 03

Milestone Pharmaceuticals - Under Agreement with Everest, Co Eligible for up to $98 Mln in Milestones and up to 18% Royalties in Greater China

THOMSON REUTERS
·
Sep 03

Milestone Pharmaceuticals Announces Nmpa Approval of Etripamil Nasal Spray for Psvt in China, Marking First Regulatory Approval of Etripamil Outside of the United States

THOMSON REUTERS
·
Sep 03

Milestone Pharma to Present at Wells Fargo Annual Healthcare Conference

Reuters
·
Sep 02

Milestone Pharmaceuticals Study Finds PSVT Curbs Daily Activities, Drives Anxiety Between Episodes

Reuters
·
Aug 27

Milestone Starts Phase 3 Trial of Nasal Spray for Atrial Fibrillation With Rapid Heart Rate

MT Newswires Live
·
Aug 21

Milestone Pharmaceuticals enrolls first patient in ReVeRA-301 pivotal trial

TIPRANKS
·
Aug 21

Milestone Pharmaceuticals Enrolls First Patient in Phase 3 ReVeRA-301 Trial of Etripamil Nasal Spray for AFib-RVR

Reuters
·
Aug 21

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (Afib-Rvr)

THOMSON REUTERS
·
Aug 21

Milestone Pharmaceuticals: Currently Pursuing Single-Study Supplemental New Drug Application (Snda) Registration Pathway for Treatment of Afib-Rvr

THOMSON REUTERS
·
Aug 21

Cantor starts Milestone Pharmaceuticals at Overweight, sees 200% upside

TIPRANKS
·
Aug 20

Milestone Pharmaceuticals Price Target Announced at $3.00/Share by Cantor Fitzgerald

Dow Jones
·
Aug 20

Milestone Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Canada's Milestone Pharma Misses Q2 Product Revenue Expectations

Reuters
·
Aug 12

Milestone Pharmaceuticals Q2 Income from Operations USD -25.63 Million

THOMSON REUTERS
·
Aug 12

Milestone Pharmaceuticals Q2 Revenue USD 559 Thousand VS. Ibes Estimate USD 816.7 Thousand

THOMSON REUTERS
·
Aug 12

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 12